Table 1.
Patient characteristics | Absolute number of patients | Percentage of patients (%) |
---|---|---|
Total number of patients | 28 | 100% |
Age (years) | ||
Median | 67.5 years | |
Range | 46 to 89 years | |
Sex (no.) | ||
Male | 13 | 46% |
Female | 15 | 54% |
Prior palliative lines (no.) | ||
FOLFIRINOX | 18 | 64% |
Gemcitabine /nab-Paclitaxel | 23 | 82% |
Gemcitabine mono (± experimental antibody) | 4 | 14% |
Nal-Irinotecan/5-FU | 3 | 11% |
Liposomal doxorubicin as palliative chemotherapy (no.) | ||
2nd line | 5 | 18% |
3rd line | 18 | 64% |
4th line | 4 | 14% |
5th line | 1 | 4% |
Metastasis at start of liposomal doxorubicin (no.) | ||
Hepatal | 18 | 64% |
Pulmonary | 8 | 29% |
Peritoneal | 5 | 18% |
Bone | 1 | 4% |
Adrenal | 1 | 4% |
metastases in ≥ 1 organ | 6 | 21% |